imbruvica
AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica
US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …
Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study
June 14, 2016Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica
Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …
FDA expands Imbruvica label with new survival data
May 11, 2016Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III
The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …
AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL
March 7, 2016Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica
Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
European Imbruvica approval for Janssen
July 20, 2015Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer
Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
Amgen’s colorectal cancer drug EU approved
April 8, 2015Sales and Marketing Amgen, Vectibix, ibrutinib, imbruvica, panitumumab, ristempa
The European Commission has shown Amgen’s cancer drug Vectibix the green light to treat patients in combination with chemotherapy for …
AbbVie buys Pharmacyclics in $21 billion deal
March 5, 2015Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica
AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
BMS, Pharmacyclics and Janssen collaborate on cancer
October 14, 2014Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo
Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
FDA extends licence for Janssen’s Imbruvica
February 13, 2014Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia
Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …
Latest content
FibroFind appoints Lee Borthwick as CEO
